[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:iga-nephropathy":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":161,"states":162},"IgA Nephropathy",24,20,[8,16,22,29,35,41,47,53,59,66,73,79,85,92,98,104,110,116,122,128,134,142,148,155],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07024563","Study of Ravulizumab in Pediatric Participants With Primary IgAN",[12],"Phase 3","RECRUITING","2026-08-26T02:17:01.714035Z","2026-07-30T01:46:14.415798Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05797610","A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression",[12],"2026-08-03T00:55:55.352869Z","2026-07-05T05:32:16.812715Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT07146906","A Study to Assess the Effects of Zigakibart on IgA Nephropathy.",[26],"Phase 2","2026-08-26T02:15:48.613507Z","2026-07-05T05:32:16.734966Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06963827","A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy",[12],"2026-08-26T02:18:58.958025Z","2026-07-05T05:32:16.723314Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06935357","A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)",[12],"2026-08-26T02:18:49.989941Z","2026-07-05T05:32:16.704128Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT07541287","A Study of JADE101 in Participants With Immunoglobulin A Nephropathy",[26],"2026-08-26T02:18:52.966503Z","2026-05-29T15:36:40.231805Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06676579","Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)",[26],"2026-08-26T02:19:06.150683Z","2026-05-05T02:43:29.703464Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT06797518","Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN",[26],"2026-08-26T02:16:08.402952Z","2026-05-05T02:43:28.872779Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":64,"content_modified":65},"NCT06712407","Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy",[63],"Phase 4","2026-08-26T02:19:09.651016Z","2026-05-05T02:43:28.857796Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":71,"content_modified":72},"NCT07182227","PS-002 for the Treatment of IgA Nephropathy in Adults",[70],"Phase 1\u002FPhase 2","2026-08-26T02:18:22.309547Z","2026-05-05T02:43:28.342179Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06994845","Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN",[12],"2026-08-26T02:19:10.436356Z","2026-05-05T02:43:28.187078Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06740526","Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue",[26],"2026-08-26T02:18:38.865010Z","2026-05-05T02:43:26.950514Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":90,"content_modified":91},"NCT07054684","Study of BHV-1400 in IgA Nephropathy",[89],"Phase 1","2026-08-26T02:15:14.574786Z","2026-05-05T02:43:26.933401Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT06858319","Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.",[12],"2026-08-26T02:15:56.561131Z","2026-04-29T02:57:57.120037Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT06989359","Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease",[26],"2026-08-26T02:15:40.343619Z","2026-05-05T02:35:31.644706Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT06983028","Atacicept in Multiple Glomerular Diseases",[26],"2026-08-26T02:17:42.501124Z","2026-07-05T05:32:16.725563Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT06466135","Study of WAL0921 in Patients With Glomerular Kidney Diseases",[26],"2026-08-26T02:17:48.768272Z","2026-05-05T02:43:28.312447Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT05003986","Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases",[26],"2026-08-26T02:17:00.709807Z","2026-04-29T02:57:57.147910Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT06952426","A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US",[],"2026-08-26T02:16:07.529922Z","2026-05-13T02:55:06.593788Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT01802034","Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)",[],"2026-08-26T02:16:49.565137Z","2026-05-13T02:55:06.077698Z",{"nct_id":135,"title":136,"phases":137,"status":139,"updated_at":140,"content_modified":141},"NCT05248659","Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)",[138],"Phase 2\u002FPhase 3","ENROLLING_BY_INVITATION","2026-08-26T02:15:38.131683Z","2026-06-16T05:54:08.028051Z",{"nct_id":143,"title":144,"phases":145,"status":139,"updated_at":146,"content_modified":147},"NCT06674577","A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept",[26],"2026-08-26T02:15:04.877798Z","2026-06-16T05:54:07.766632Z",{"nct_id":149,"title":150,"phases":151,"status":152,"updated_at":153,"content_modified":154},"NCT07219121","Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis",[63],"ACTIVE_NOT_RECRUITING","2026-08-03T02:02:26.137944Z","2026-05-05T02:43:29.153210Z",{"nct_id":156,"title":157,"phases":158,"status":152,"updated_at":159,"content_modified":160},"NCT06291376","Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)",[12],"2026-08-03T03:37:48.267540Z","2026-04-29T02:57:57.115885Z",[],[163,167,170,174,178,181,185,188,192,196,200,203,206,210,213,216,219,223,226,229,232,235,239,242],{"state":164,"count":165,"slug":166},"Florida",15,"florida",{"state":168,"count":165,"slug":169},"Texas","texas",{"state":171,"count":172,"slug":173},"California",13,"california",{"state":175,"count":176,"slug":177},"Georgia",10,"georgia",{"state":179,"count":176,"slug":180},"New York","new-york",{"state":182,"count":183,"slug":184},"Colorado",9,"colorado",{"state":186,"count":183,"slug":187},"Ohio","ohio",{"state":189,"count":190,"slug":191},"Massachusetts",8,"massachusetts",{"state":193,"count":194,"slug":195},"Alabama",7,"alabama",{"state":197,"count":198,"slug":199},"Michigan",6,"michigan",{"state":201,"count":198,"slug":202},"Minnesota","minnesota",{"state":204,"count":198,"slug":205},"Missouri","missouri",{"state":207,"count":208,"slug":209},"Iowa",5,"iowa",{"state":211,"count":208,"slug":212},"North Carolina","north-carolina",{"state":214,"count":208,"slug":215},"Pennsylvania","pennsylvania",{"state":217,"count":208,"slug":218},"South Dakota","south-dakota",{"state":220,"count":221,"slug":222},"Arizona",4,"arizona",{"state":224,"count":221,"slug":225},"Illinois","illinois",{"state":227,"count":221,"slug":228},"Louisiana","louisiana",{"state":230,"count":221,"slug":231},"Utah","utah",{"state":233,"count":221,"slug":234},"Wisconsin","wisconsin",{"state":236,"count":237,"slug":238},"Idaho",3,"idaho",{"state":240,"count":237,"slug":241},"Nevada","nevada",{"state":243,"count":237,"slug":244},"Tennessee","tennessee"]